US › Healthcare

Collplant Biotechnologies Ltd (CLGN)

US · Healthcare · Biotechnology

$4.16+19.54%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

$73,000

Revenue YoY

-96.4%

Net profit

$-3.1M

EPS

$-2.80

EPS estimate

$-0.24

Net margin

-4,242.5%

EPS came in at -2.80 against a street estimate of -0.24 — a miss of 1066.7%.

Key statistics

Market cap

$6.6M

Forward P/E

80.0

P/B

1.32

Book value

$3.39

EPS (TTM)

$-10.71

52-week high

$31.80

52-week low

$2.64

50-day MA

$3.30

200-day MA

$7.25

Beta

0.74

Analyst view

Analysts rate Collplant Biotechnologies Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.12.

Shareholding

Insiders

30.86%

Institutions

9.93%

Largest institutional holders

Fund	Stake
Parallel Advisors, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Collplant Biotechnologies Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.